Gepotidacin was approved by the FDA earlier this year, under the Blujepa brand, as the first oral antibiotic to offer a new ...

One major and often overlooked factor contributing to this imbalance is the way health outcomes are measured in clinical ...

One near-term rival is Johnson & Johnson's FcRn inhibitor nipocalimab, which started a phase 3 programme last December.

Boehringer Ingelheim's bid to return to the oncology arena has been achieved with an FDA approval for Hernexeos, a new, ...

The word from the FDA is that Prasad has come back at the request of the regulator's Commissioner, Marty Makary, who ...

Haematological cancers are a recognised potential side effect with Skysona and were already mentioned in a boxed warning on the gene therapy's approved labelling. The new label restricts use of the ...

Strand Therapeutics has raised $153 million in second-round financing that will be used to move its programmable mRNA ...

A jury in the US has found that tech giant Meta illegally compromised the privacy of a US woman who shared her data with a ...

In Part Two, putting theory into practice is addressed.

The joint information sharing agreement between the medicines regulatory authority and reimbursement agency was first ...

In its second-quarter financial filing, Iovance said it was planning to shed 19% of its workforce of more than 630 in order ...

For comparison, Lilly's arch-rival in the weight-loss category, Novo Nordisk, is developing an oral formulation of ...